<DOC>
	<DOCNO>NCT00003301</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness irinotecan treating patient recurrent malignant glioma .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intravenous irinotecan administer weekly 4 week patient recurrent malignant glioma . II . Describe pharmacokinetics route administration , measure irinotecan active metabolite SN-38 , determine effect hepatic enzyme induce drug , anticonvulsant , pharmacokinetics patient . III . Determine preliminary response data activity irinotecan patient population . IV . Correlate response topoisomerase I level brain tumor tissue patient undergoing treatment . OUTLINE : Patients stratify base use/kind anticonvulsant drug . This stratification yield two arm study . Arm I consist patient use anticonvulsant drug induce hepatic metabolic enzyme . Arm II consist patient use anticonvulsant drug cause modest induction hepatic metabolic enzyme anticonvulsant drug . Three patient arm receive irinotecan 90-minute IV infusion every week 4 week , follow 2 week rest period . The dose escalate next cohort 3 patient absence unacceptable dose limit toxicity . The 6 week course repeat unacceptable toxicity disease progression . Once maximum tolerate dose establish arm , additional patient treat dose level . Patients follow every 2 month . PROJECTED ACCRUAL : A minimum 3 patient accrued phase I portion study total 18-35 patient accrue arm phase II portion study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma progressive recurrent follow radiation therapy chemotherapy Anaplastic astrocytoma Glioblastoma multiforme Low grade glioma progress biopsy proven high grade glioma eligible progression occur radiotherapy without chemotherapy Measurable progression recurrence serial MR CT image PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 2 month Hematopoietic : Absolute neutrophil count 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Renal : Creatinine great 1.7 mg/dL Cardiovascular : No uncontrolled hypertension No angina pectoris No evidence uncontrolled cardiac dysrhythmia Other : No serious infection medical illness No prior concurrent malignancy within 5 year except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix breast Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior topoisomerase 1 inhibitor ( topotecan , irinotecan , 9 aminocamptothecin ) No 1 prior chemotherapy regimen At least 6 week since nitrosourea recover At least 3 week since chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 month since completion recent course radiotherapy recover Surgery : Not specify Other : No concurrent investigational agent At least 14 day since prior valproic acid No concurrent valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>